---
title: "AIM ImmunoTech's rights offering expired with $1.8 million in subscriptions for their lead product, Ampligen®, targeting pancreatic cancer."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277794999.md"
description: "AIM ImmunoTech Inc., a company specializing in immuno-pharma, revealed the initial outcomes of its recently concluded Rights Offering which ended on March 3, 2026, at 5:00 p.m. EST. The estimated total subscriptions from the Rights Offering are around $1.8 million. AIM ImmunoTech is concentrated on advancing Ampligen® (rintatolimod) to combat late-stage pancreatic cancer, a challenging global health issue. These results are preliminary and await confirmation by the company and its subscription agent, Broadridge Corporate Issuer Solutions, LLC."
datetime: "2026-03-04T14:02:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277794999.md)
  - [en](https://longbridge.com/en/news/277794999.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277794999.md)
---

# AIM ImmunoTech's rights offering expired with $1.8 million in subscriptions for their lead product, Ampligen®, targeting pancreatic cancer.

AIM ImmunoTech Inc., a company specializing in immuno-pharma, revealed the initial outcomes of its recently concluded Rights Offering which ended on March 3, 2026, at 5:00 p.m. EST. The estimated total subscriptions from the Rights Offering are around $1.8 million. AIM ImmunoTech is concentrated on advancing Ampligen® (rintatolimod) to combat late-stage pancreatic cancer, a challenging global health issue. These results are preliminary and await confirmation by the company and its subscription agent, Broadridge Corporate Issuer Solutions, LLC.

### Related Stocks

- [AIM.US](https://longbridge.com/en/quote/AIM.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)

## Related News & Research

- [Pancreatic cancer pill shown to nearly double overall survival time, drug company says](https://longbridge.com/en/news/282687539.md)
- [BUZZ-Street View: Analysts upbeat on Revolution pancreatic cancer drug](https://longbridge.com/en/news/282702171.md)
- [Novo Nordisk Partners with OpenAI to Boost Drug Development, Delivery](https://longbridge.com/en/news/282641629.md)
- [Revolution Medicines Says Daraxonrasib Shows Improvement In Survival In Late-Stage Pancreatic Cancer Study](https://longbridge.com/en/news/282550417.md)
- [Sino Biopharmaceutical Receives US Regulatory Nod to Begin Trials of Anti Tumor Drug](https://longbridge.com/en/news/282121816.md)